Ignite Creation Date:
2024-05-06 @ 12:23 PM
Last Modification Date:
2024-10-26 @ 12:58 PM
Study NCT ID:
NCT03747965
Status:
UNKNOWN
Last Update Posted:
2018-11-20
First Post:
2018-11-19
Brief Title:
Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors
Sponsor:
Chinese PLA General Hospital
Organization:
Chinese PLA General Hospital
Study Overview
Official Title:
Phase I Study of CRISPR-Cas9 Mediated PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning Regimen of Paclitaxel and Cyclophosphamide in Mesothelin Positive Multiple Solid Tumors
Status:
UNKNOWN
Status Verified Date:
2018-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multiple solid tumors have positive targets of mesothelin expressed on the surfaces of the tumor cells the investigators use the technique of CRISPR-Cas9 to knocked out the PD-1 of the chimeric antigen receptor CAR T cells with the combination of Pretreatment by Paclitaxel and Cyclophosphamideto to effect the immuno-microenvironment around tumors
Detailed Description:
1 To evaluate the feasibility and safety of CRISPR-Cas9 mediated PD-1 gene-knocked out chimeric antigen receptor CAR T cells in patients with mesothelin positive multiple solid tumors
2 To evaluate the duration and in vivo persistence of transferred CAR-T cells
3 To observe and measure anti-tumor responses for patients with detectable mesothelin positive tumor lesions
2 To evaluate the duration and in vivo persistence of transferred CAR-T cells
3 To observe and measure anti-tumor responses for patients with detectable mesothelin positive tumor lesions
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None